KT-333   Click here for help

GtoPdb Ligand ID: 13369

Compound class: Synthetic organic
Comment: KT-333 is a VHL-based STAT3 PROTAC degrader. STAT3 is a transcriptional regulator whose activity has been associated with the development of cancers, and to inflammatory and autoimmune diseases. The structure of the molecule presented here was obtained from Drug Hunter (April 2024). This chemical structure is closely related to STAT3 degrader I-241 in Kymera patent US11485750B1 which has additional specified stereo centers [1]. We await formal disclosure of KT-333's structure in peer-reviewed literature (May 2024).
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 24
Hydrogen bond donors 9
Rotatable bonds 29
Topological polar surface area 383.98
Molecular weight 1257.78
XLogP -0.6
No. Lipinski's rules broken 4
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H](C1=CC=C(C=C1)C2=C(C)N=CS2)NC(=O)C3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCC4=CC=CC(=C4Cl)OC[C@H](CCC(=O)N)NC(=O)C5CC[C@@H]6CCN(C[C@@H](C(=O)N65)NC(=O)C7=CC8=C(C=CC(=C8)C(=O)P(=O)(O)O)N7)C(=O)C)O
Isomeric SMILES C[C@H](NC(=O)C1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)CCCC2=C(Cl)C(OC[C@H](CCC(N)=O)NC(=O)C3CC[C@@H]4CCN(C[C@H](NC(=O)C5=CC6=C(N5)C=CC(=C6)C(=O)P(O)(O)=O)C(=O)N34)C(C)=O)=CC=C2)C(C)(C)C)C7=CC=C(C=C7)C8=C(C)N=CS8
InChI InChI=1S/C60H74ClN10O14PS/c1-32(35-13-15-37(16-14-35)52-33(2)63-31-87-52)64-56(78)47-27-42(73)28-70(47)58(80)53(60(4,5)6)68-50(75)12-8-10-36-9-7-11-48(51(36)61)85-30-40(18-22-49(62)74)65-55(77)46-21-19-41-23-24-69(34(3)72)29-45(57(79)71(41)46)67-54(76)44-26-39-25-38(17-20-43(39)66-44)59(81)86(82,83)84/h7,9,11,13-17,20,25-26,31-32,40-42,45-47,53,66,73H,8,10,12,18-19,21-24,27-30H2,1-6H3,(H2,62,74)(H,64,78)(H,65,77)(H,67,76)(H,68,75)(H2,82,83,84)/t32-,40-,41+,42+,45-,46?,47?,53+/m0/s1
InChI Key OANZCHOMQTZJOO-GKGQXZCKSA-N
No information available.
Summary of Clinical Use Click here for help
KT-333 is a clinical candidate for the treatment of STAT3-dependent haematological malignancies and solid tumours. The FDA granted orphan designation in September 2022 (for relapsed/refractory cutaneous and peripheral T cell lymphomas), with fast track designation following one year later.